BPC
CPRX icon

Bryce Point Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Bryce Point Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,608
Closed -$507K – 199
2025
Q1 		$507K Sell
20,608
-33,750
-62% -$760K 0.38% 152
2024
Q4 		$1.13M Buy
+54,358
New +$1.17M 0.33% 123

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bryce Point Capital's CPRX Position: Q2 2025 in Review

Bryce Point Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 20,608 shares — an estimated $507K sold.

Bryce Point Capital first reported a position in CPRX in Q4 2024 and held it in 2 quarters. The position peaked at $1.13M in Q4 2024. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • Bryce Point Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Bryce Point Capital sold 20,608 Catalyst Pharmaceutical shares in Q2 2025, an estimated $507K.
  • Bryce Point Capital first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 2 quarters.
  • Bryce Point Capital's Catalyst Pharmaceutical position peaked at $1.13M in Q4 2024.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Bryce Point Capital's 13F filing for Q2 2025, filed 5 Aug 2025.